VSIR and neoplasm: Recent studies have demonstrated that anti-tumor immunity, particularly T cell-mediated immunity, and the effectiveness of responses to tumor-associated antigens may be promoted by either genetic VISTA deficiency or the use of an anti-VISTA monoclonal antibody antagonist (66, 67).